Akums Corporation Reveals 19% Year-Over-Year Expansion in Adjusted EBITDA for Q1 FY26; Secures 1,000 Approvals from DCGI
Akums Drugs and Pharmaceuticals Poised to Capitalise on Growing Market for Combination Drugs
Akums Drugs and Pharmaceuticals Ltd., an Indian Contract Development and Manufacturing Organization (CDMO), is gearing up to enter critical international markets with the commercialisation of the Rivaroxaban and Dapagliflozin combination. This strategic move is backed by significant regulatory milestones and robust financial support.
The European Union (EU) dossier approval for Rivaroxaban and the Swiss filing for the Dapagliflozin combination mark important steps, allowing Akums to supply these drugs commercially in Europe and Switzerland starting April 2027. These approvals not only enhance Akums' credibility and market access globally but also position the company to capitalise on the considerable generic market opportunities arising from the impending patent expiry of these blockbuster drugs.
Rivaroxaban, a thrombosis prevention drug, and Dapagliflozin, a type 2 diabetes and heart failure therapy, are approaching patent expiry in 2025-2026 and 2025 respectively. This timing provides Akums with a strategic entry point into the product lifecycle. The combination of these drugs is expected to leverage the high demand in cardiovascular and diabetic patient segments, given their strong existing markets - Rivaroxaban with ~$4.5 billion annual sales and Dapagliflozin ~$6 billion globally.
Akums has received a substantial upfront payment of €100 million (approximately ₹880 crore) from a €200 million European CDMO contract tied to these products, demonstrating financial backing and market confidence. The company's robust liquidity of ₹1,518 crore cash surplus further supports scaling production and market entry efforts.
The company's strategic vision aligns with its ambition to grow as a global CDMO and commercial player. Akums has already achieved over 1,000 Drug Controller General of India (DCGI) approvals and is currently working on ongoing R&D momentum.
In the first quarter of the financial year 2026 (Q1 FY26), Akums reported a total income of Rs. 1,051 crore, with an Adjusted PAT Margin of 6.2%. The Adjusted EBITDA Margin stood at 14.8%, representing a 19.1% year-on-year growth, and the Adjusted EBITDA for Q1 FY26 was Rs. 156 crore. The company's focus remains on strengthening CDMO leadership, scaling high-value capabilities, and driving operational excellence.
In addition to these developments, Akums has also received its first EU dossier approval for Rivaroxaban and filed its first dossier of the Dapagliflozin combination in Switzerland. The company has also reported 27 fresh DCGI approvals in Q1 FY26.
With the market potential for the Rivaroxaban and Dapagliflozin combination being significant, Akums Drugs and Pharmaceuticals Ltd. is well-positioned to capture this growing market post-patent expiry, promising substantial revenue potential from the Rivaroxaban-Dapagliflozin combination starting 2027 onwards.
Akums Drugs and Pharmaceuticals Ltd. is planning to invest in technology and finance to scale the production of their Rivaroxaban and Dapagliflozin combination, leveraging the high demand in the cardiovascular and diabetic patient segments. Having received substantial upfront payment and with a robust financial support, Akums is poised to capitalize on the generic market opportunities arising from the impending patent expiry of these blockbuster drugs, targeting significant revenue potential from the Rivaroxaban-Dapagliflozin combination starting 2027 onwards.
